Losartan Potassium Tablet, Film Coated
Product Images NDC 0904-7047

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 0904-7047). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losapotatab1 (C516a5a7 Cfc8 4b3b A8bc 7644c3313673 01)

Chemical structure diagram of Losartan Potassium showing its molecular configuration including the potassium ion.*

FDA Label Image

Losapotatab2 (C516a5a7 Cfc8 4b3b A8bc 7644c3313673 02)

A line graph comparing the percentage of patients with primary endpoints over study months for Atenolol (dashed line) and Losartan Potassium (solid line). The x-axis represents study months from 0 to 66, and the y-axis represents the percentage of patients with primary endpoints from 0 to 16%. The graph shows an adjusted risk reduction of 13% for Losartan Potassium with p=0.021.*

FDA Label Image

Losapotatab3 (C516a5a7 Cfc8 4b3b A8bc 7644c3313673 03)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over study months between Atenolol and Losartan Potassium. The x-axis represents study months from 0 to 66, and the y-axis shows the percentage of patients from 0 to 8%. Two lines depict outcomes: a dashed line for Atenolol and a solid line for Losartan Potassium, with Losartan showing a lower stroke rate. The graph notes an adjusted risk reduction of 25% with a p-value of 0.001.*

FDA Label Image

Losapotatab (C516a5a7 Cfc8 4b3b A8bc 7644c3313673 04)

A comparative hazard ratio forest plot chart showing the event rates of Losartan-K versus Atenolol in patients by subgroups for primary composite and stroke (fatal/non-fatal) outcomes. The plot breaks down data by age, gender, race, ISH status, diabetes presence, and history of cardiovascular disease, indicating favorability toward either drug based on hazard ratio with 95% confidence intervals.*

FDA Label Image

Losapotatab5 (C516a5a7 Cfc8 4b3b A8bc 7644c3313673 05)

A line graph comparing the percentage of patients with an event over 48 months between Losartan Potassium Tablet and placebo groups. The graph shows cumulative event rates with Losartan Potassium having a lower percentage, indicating a 16.1% risk reduction (p=0.022).*

FDA Label Image

Carton Label (Image 01)

Losartan Potassium 25 mg film-coated tablets label from Major Pharmaceuticals. The unit dose package contains 100 tablets for oral administration. The label includes dosage strength, manufacturer details, NDC number 0904-7047-61, and storage instructions.*

FDA Label Image

Carton Label (Image 02)

Losartan Potassium tablets, USP 50 mg film-coated oral tablets by Major Pharmaceuticals. The label includes the NDC number 0904-7048-61 and indicates the package contains 100 tablets for prescription use only. It states that each tablet contains 50 mg of losartan potassium and includes storage instructions and dispensing information.*

FDA Label Image

Carton Label (Image 03)

Losartan Potassium 100 mg film-coated tablets packaging label by Major Pharmaceuticals. The label states the product is a unit dose and includes 100 tablets. It contains instructions for pharmacists to dispense with patient information, storage conditions at 20° to 25°C, and handling guidelines. The label also includes NDC 0904-7049-61 and manufacturer and distributor details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.